| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000034228 |
| Receipt No. | R000039020 |
| Scientific Title | Effects of pimobendan on prolonging time to rehospitalization or frequency of readmission in patients with heart failure.-a retrospective cohort study using medical administrative database-(PREFER study) |
| Date of disclosure of the study information | 2018/10/01 |
| Last modified on | 2019/03/27 (Ver. 3) |
| Basic information | ||
| Public title | Effects of pimobendan on prolonging time to rehospitalization or frequency of readmission in patients with heart failure.-a retrospective cohort study using medical administrative database-(PREFER study) | |
| Acronym | Effects of pimobendan on prolonging time to rehospitalization or frequency of readmission in patients with heart failure.-a retrospective cohort study using medical administrative database-(PREFER study) | |
| Scientific Title | Effects of pimobendan on prolonging time to rehospitalization or frequency of readmission in patients with heart failure.-a retrospective cohort study using medical administrative database-(PREFER study) | |
| Scientific Title:Acronym | Effects of pimobendan on prolonging time to rehospitalization or frequency of readmission in patients with heart failure.-a retrospective cohort study using medical administrative database-(PREFER study) | |
| Region |
|
|
| Condition | |||
| Condition | Heart Failure | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To study exploratory the influence of pimobendan prescription on prolonging time to rehospitalization and/or incident of readmission for heart failure patient utilizing medical administrative database. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | The time to rehospitalization and/or the incident of readmission in heart failure patient. |
| Key secondary outcomes | Number of re-hospitalization due to heart failure
Total number of hospitalizations Frequency of specific adverse event for cardiotonic drugs |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Patients who have more than 2 records of hospitalization between the study target period from January 2010 to February 2018.
2. Patients who have more than 2 records of hospitalization under disease name of heart failure (ICD10 code:I11.0,I50) which is considered as a reason behind hospitalization. 3. Patients who have more than 2 records of outpatient visit after the start of the follow-up period. 4. Patient who are older than 20 years at the start of the follow-up period. |
|||
| Key exclusion criteria | 1.Patients whom had discharge JCS score was more than 1 at the hospitalization at the start of follow-up period.
2.Patients whom had discharge ADL score was less than 12 at the hospitalization at the start of follow-up period. 3.Patients who received pimobendan short term prescription. 4.Patients who have prescribed Vesnarinone,Denopamine,Docarpamine,during the follow-up period. 5.Patients who are prescribed inotropic injections(Dopamine hydrochloride,Dobutamine hydrochloride,PDE3inhibitors or Colforsin daropate hydrochloride) at the outpatient visits during the follow-up period. 6.Patients who had the following records within 90 days prior to the start of the follow-up period: -Cardiac surgery(CABG,Valvuloplasty,Valve replacement surgery,etc.)(category code; K522,K554,K555,K5763,K5792,Including combined operation cases.) -TAVI(category code;K555-02) -Cardiac resynchronization therapy(CRT)(category code;K598,K598-02,K599-03,K599-04) -PCI(category code;K546,K547,K548,K549,K550) 7.Patient who have the following diagnosis or procedures within the study target period:Malignant tumor(ICD10;C00-C97) -Heart transplantation(category code;K605-02) -Left Ventricular Assist Device(LVAD)(category code;C116,K603,K6042,K604-02) |
|||
| Target sample size | 1000 | |||
| Research contact person | |||||||
| Last name of lead principal investigator |
|
||||||
| Organization | Saiseikai Kumamoto Hospital | ||||||
| Division name | Cardiology | ||||||
| Zip code | 861-4193 | ||||||
| Address | 5-3-1 Chikami,Minami-ku,Kumamoto-city, Japan | ||||||
| TEL | 096-351-8000 | ||||||
| koichi-nakao@saiseikaikumamoto.jp | |||||||
| Public contact | |||||||
| 1st name of contact person |
|
||||||
| Organization | Crecon Medical Assessment Inc. | ||||||
| Division name | NA | ||||||
| Zip code | 150-0002 | ||||||
| Address | Nagai Memorial Bldg. 12-5,Shibuya 2-chome,Shibuya-ku,Tokyo Japan | ||||||
| TEL | 03-3407-4491 | ||||||
| Homepage URL | |||||||
| tatsunori.murata@crecon.jp | |||||||
| Sponsor | |
| Institute | Saiseikai Kumamoto Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Toa Eiyo Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Saiseikai Kumamoto Hospital Ethics Committee |
| Address | 5-3-1 Chikami,Minami-ku,Kumamoto-city, 861-4193,Japan |
| Tel | 096-351-8513 |
| naoko-takahashi@saiseikaikumamoto.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | Retrospective cohort study |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000039020 |